Elsevier

Heart Rhythm

Volume 10, Issue 12, December 2013, Pages 1932-1963
Heart Rhythm

HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes: Document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013.

https://doi.org/10.1016/j.hrthm.2013.05.014Get rights and content

Introduction

This international consensus statement is the collaborative effort of three medical societies representing electrophysiology in North America, Europe and Asian-Pacific area: the Heart Rhythm Society (HRS), the European Heart Rhythm Association (EHRA) and the Asia Pacific Heart Rhythm Society. The objective of the consensus document is to provide clinical guidance for diagnosis, risk stratification and management of patients affected by inherited primary arrhythmia syndromes. It summarizes the opinion of the international writing group members based on their own experience and on a general review of the literature with respect to the clinical data on patients affected by channelopathies.

This document does not address the indications of genetic testing in patients affected by inherited arrhythmias and their family members. Diagnostic, prognostic, and therapeutic implications of the results of genetic testing also are not included in this document because this topic has been covered by a recent publication1 coauthored by some of the contributors of this consensus document, and it remains the reference text on this topic. Guidance for the evaluation of patients with idiopathic ventricular fibrillation, sudden arrhythmic death syndrome and sudden unexplained death in infancy, which includes genetic testing, are provided as these topics were not covered in the previous consensus statement.

Developing guidance for genetic diseases requires adaptation of the methodology adopted to prepare guidelines for clinical practice. Documents produced by other medical societies have acknowledged the need to define the criteria used to rank the strength of recommendation for genetic diseases.2

The most obvious difference encountered for inherited diseases is that randomized and/or blinded studies do not exist in this field. Therefore most of the available data derive from registries that have followed patients and recorded outcome information. As a consequence, all consensus recommendations are level of evidence (LOE) C (i.e., based on experts’ opinions).

The consensus recommendations in this document use the commonly used Class I, IIa, IIb and III classification and the corresponding language: “is recommended” for Class I consensus recommendation; “can be useful” for a Class IIa consensus recommendation; “may be considered” to signify a Class IIb consensus recommendation; and “should not” or “is not recommended” for a Class III consensus recommendation (failure to provide any additional benefit and may be harmful).

In the consensus document, the following terms will be defined as:

  • Syncope: In the context of inherited arrhythmogenic disorders, the occurrence of “syncope” is an important indicator of arrhythmic risk. Although there is no definition to differentiate a syncopal episode caused by ventricular arrhythmias from an otherwise unexplained syncope, in the context of this document, the term “syncope” implies the exclusion of events that are likely due to vasovagal events such as those occurring during abrupt postural changes, exposure to heat and dehydration, emotional reactions to events such as blood drawing, etc. We refer to the guidelines of ESC and AHA/ACCF for the differential diagnoses of syncope.3, 4 Symptomatic individuals: The term “symptomatic” refers to individuals who have experienced ventricular arrhythmias (usually ventricular tachycardia or resuscitated ventricular fibrillation), or syncopal episodes (see definition above). The presence of symptoms is, in some of the channelopathies, an independent predictor of cardiac arrest at follow-up.

  • Arrhythmic events: The term refers to the occurrence of symptomatic or asymptomatic sustained or nonsustained spontaneous ventricular tachycardia, or unexplained syncope/resuscitated cardiac arrest.

  • Concealed mutation-positive patients: This term is used to refer to individuals without clinical symptoms or phenotype of a channelopathy who carry the genetic defect present in clinically affected members of the family.

When considering the guidance from this document, it is important to remember that there are no absolutes governing many clinical situations. The final judgment regarding care of a particular patient must be made by the health care provider and the patient in light of all relevant circumstances. Recommendations are based on consensus of the writing group following the Heart Rhythm Society’s established consensus process. It is recognized that consensus does not mean unanimous agreement among all writing group members. We identified the aspects of patients' care for which a true consensus could be found. Surveys of the entire writing group were used. The authors received an agreement that was equal to or greater than 84% on all recommendations; most recommendations received agreement of 94% or higher.

This statement is directed to all health care professionals who are involved in the management of (1) individuals who survived a cardiac arrest at a young age (usually defined as <40 years) in the absence of a clinical diagnosis of cardiac disease, despite extensive clinical assessment; (2) family members of individuals who died suddenly at young age with a negative autopsy; (3) in patients and family members in whom the diagnosis of a channelopathy is clinically possible, likely, or established; and (4) young patients with unexplained syncope.

All members of this document writing group provided disclosure statements of all relationships that might present real or perceived conflicts of interest. Disclosures for all members of the writing group are published in Appendix A.

Section snippets

Long QT Syndrome (LQTS)

Expert Consensus Recommendations on LQTS Diagnosis
  • 1.

    LQTS is diagnosed:

    • a.

      In the presence of an LQTS risk score ≥3.5 in the absence of a secondary cause for QT prolongation and/or

    • b.

      In the presence of an unequivocally pathogenic mutation in one of the LQTS genes or

    • c.

      In the presence of a QT interval corrected for heart rate using Bazett's formula (QTc) ≥500 ms in repeated 12-lead electrocardiogram (ECG) and in the absence of a secondary cause for QT prolongation.

  • 2.

    LQTS can be diagnosed in the presence of a

Brugada Syndrome (BrS)

Expert Consensus Recommendations on Brugada Syndrome Diagnosis
  • 1.

    BrS is diagnosed in patients with ST-segment elevation with type 1 morphology ≥2 mm in ≥1 lead among the right precordial leads V1, V2, positioned in the 2nd, 3rd or 4th intercostal space occurring either spontaneously or after provocative drug test with intravenous administration of Class I antiarrhythmic drugs.

  • 2.

    BrS is diagnosed in patients with type 2 or type 3 ST-segment elevation in ≥1 lead among the right precordial leads V1, V2

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Expert Consensus Recommendations on CPVT Diagnosis
  • 1.

    CPVT is diagnosed in the presence of a structurally normal heart, normal ECG, and unexplained exercise or catecholamine-induced bidirectional VT or polymorphic ventricular premature beats or VT in an individual <40 years of age.

  • 2.

    CPVT is diagnosed in patients (index case or family member) who have a pathogenic mutation.

  • 3.

    CPVT is diagnosed in family members of a CPVT index case with a normal heart who manifest exercise-induced PVCs or

Sjome (SQTS)

Expert Consensus Recommendations on Short QT Syndrome Diagnosis
  • 1.

    SQTS is diagnosed in the presence of a QTc ≤330 ms.

  • 2.

    SQTS can be diagnosed in the presence of a QTc <360 ms and one or more of the following: a pathogenic mutation, family history of SQTS, family history of sudden death at age ≤40, survival of a VT/VF episode in the absence of heart disease.

Expert Consensus Recommendations on Short QT Syndrome Therapeutic Interventions
Class I
  • 1.

    ICD implantation is recommended in symptomatic patients with

Early Repolarization (ER)

Expert Consensus Recommendations on Early Repolarization Diagnosis
  • 1.

    ER syndrome is diagnosed in the presence of J-point elevation ≥1 mm in ≥2 contiguous inferior and/or lateral leads of a standard 12-lead ECG in a patient resuscitated from otherwise unexplained VF/polymorphic VT

  • 2.

    ER syndrome can be diagnosed in an SCD victim with a negative autopsy and medical chart review with a previous ECG demonstrating J-point elevation ≥1 mm in ≥2 contiguous inferior and/or lateral leads of a standard 12-lead

Progressive Cardiac Conduction Disease (PCCD)

Expert Consensus Recommendations on Progressive Cardiac Conduction Disease Diagnosis
  • 1.

    Progressive cardiac conduction disease (PCCD) is diagnosed in the presence of unexplained progressive conduction abnormalities in young (<50 years) individuals with structurally normal hearts in the absence of skeletal myopathies, especially if there is a family history of PCCD.

Expert Consensus Recommendations on Progressive Cardiac Conduction Disease Therapeutic Interventions
Class I
  • 1.

    Pacemaker implantation is

Unexplained Cardiac Arrest: Idiopathic VF

Expert Consensus Recommendations on Idiopathic Ventricular Fibrillation Diagnosis
  • 1.

    IVF is defined as a resuscitated cardiac arrest victim, preferably with documentation of VF, in whom known cardiac, respiratory, metabolic and toxicological etiologies have been excluded through clinical evaluation.

Expert Consensus Recommendations on Idiopathic Ventricular Fibrillation Evaluation
Class IIa
  • 1.

    Genetic testing in IVF can be useful when there is a suspicion of a specific genetic disease following clinical

Unexplained Sudden Cardiac Death: Sudden Unexplained Death Syndrome (SUDS) and Sudden Unexplained Death in Infancy (SUDI)

Expert Consensus Recommendations on Sudden Unexplained Death Syndrome Diagnosis
  • 1.

    It is recommended that an unexplained sudden death occurring in an individual older than 1 year of age is known as “sudden unexplained death syndrome” (SUDS).

  • 2.

    It is recommended that a SUDS death with negative pathological and toxicological assessment is termed “sudden arrhythmic death syndrome” (SADS).

Expert Consensus Recommendations on Sudden Unexplained Death Syndrome Evaluation
Class I
  • 1.

    It is recommended that

Inherited Arrhythmia Clinics

Inherited Arrhythmia Clinic Expert Consensus Recommendation
Class I
Patients (probands) and first-degree relatives with a diagnosed or suspected inherited cardiovascular disease as a potential cause of SCD (SUDS/SUDI) should be evaluated in a dedicated clinic with appropriately trained staff.

The evaluation and treatment of families suspected of having inherited arrhythmias requires a multidisciplinary team and approach. The presentation often is that of a proband or family member who has

References (242)

  • I. Splawski et al.

    Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism

    Cell

    (2004)
  • D. Migdalovich et al.

    Mutation and gender-specific risk in type 2 long QT syndrome: implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome

    Heart Rhythm

    (2011)
  • W. Shimizu et al.

    Genotype-phenotype aspects of type 2 long QT syndrome

    J Am Coll Cardiol

    (2009)
  • P.J. Schwartz et al.

    All LQT3 patients need an ICD: true or false?

    Heart Rhythm

    (2009)
  • C. Spazzolini et al.

    Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy

    J Am Coll Cardiol

    (2009)
  • P. Chockalingam et al.

    Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol

    J Am Coll Cardiol

    (2012)
  • C. Jons et al.

    Risk of fatal arrhythmic events in long QT syndrome patients after syncope

    J Am Coll Cardiol

    (2010)
  • J.M. Horner et al.

    Implantable cardioverter defibrillator therapy for congenital long QT syndrome: a single-center experience

    Heart Rhythm

    (2010)
  • E.S. Kaufman et al.

    Risk of death in the long QT syndrome when a sibling has died

    Heart Rhythm

    (2008)
  • K. Ouriel et al.

    Long QT syndrome: an indication for cervicothoracic sympathectomy

    Cardiovasc Surg

    (1995)
  • A. Odero et al.

    Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: the surgical supraclavicular approach to cervicothoracic sympathectomy

    Heart Rhythm

    (2010)
  • C.A. Collura et al.

    Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery

    Heart Rhythm

    (2009)
  • K. Miyamoto et al.

    Diagnostic and prognostic value of a type 1 Brugada electrocardiogram at higher (third or second) V1 to V2 recording in men with Brugada syndrome

    Am J Cardiol

    (2007)
  • S. Nagase et al.

    Electroanatomical correlation of repolarization abnormalities in Brugada syndrome: detection of type 1 electrocardiogram in the right ventricular outflow tract

    J Am Coll Cardiol

    (2010)
  • W. Shimizu

    Acquired forms of the Brugada syndrome

    J Electrocardiol

    (2005)
  • H. Makimoto et al.

    Augmented ST-segment elevation during recovery from exercise predicts cardiac events in patients with Brugada syndrome

    J Am Coll Cardiol

    (2010)
  • T. Ikeda et al.

    Assessment of noninvasive markers in identifying patients at risk in the Brugada syndrome: insight into risk stratification

    J Am Coll Cardiol

    (2001)
  • S.G. Priori et al.

    Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry

    J Am Coll Cardiol

    (2012)
  • H. Makimoto et al.

    Clinical impact of the number of extrastimuli in programmed electrical stimulation in patients with Brugada type 1 electrocardiogram

    Heart Rhythm

    (2012)
  • P. Brugada et al.

    Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report

    J Am Coll Cardiol

    (1992)
  • B. Benito et al.

    Gender differences in clinical manifestations of Brugada syndrome

    J Am Coll Cardiol

    (2008)
  • H. Morita et al.

    Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome

    J Am Coll Cardiol

    (2002)
  • K.F. Kusano et al.

    Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds

    J Am Coll Cardiol

    (2008)
  • P.G. Meregalli et al.

    Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies

    Heart Rhythm

    (2009)
  • M.F. Marquez et al.

    Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: a case series and literature review

    Heart Rhythm

    (2012)
  • M. Kakishita et al.

    Mode of onset of ventricular fibrillation in patients with Brugada syndrome detected by implantable cardioverter defibrillator therapy

    J Am Coll Cardiol

    (2000)
  • H. Morita et al.

    Epicardial ablation eliminates ventricular arrhythmias in an experimental model of Brugada syndrome

    Heart Rhythm

    (2009)
  • D.P. Zipes et al.

    ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society

    Circulation

    (2006)
  • Task Force for the Diagnosis and Management of Syncope, European Society of Cardiology (ESC), European Heart Rhythm...
  • S.A. Strickberger et al.

    AHA/ACCF Scientific Statement on the evaluation of syncope: from the American Heart Association Councils on Clinical Cardiology, Cardiovascular Nursing, Cardiovascular Disease in the Young, and Stroke, and the Quality of Care and Outcomes Research Interdisciplinary Working Group; and the American College of Cardiology Foundation: in collaboration with the Heart Rhythm Society: endorsed by the American Autonomic Society

    Circulation

    (2006)
  • P.J. Schwartz et al.

    Prevalence of the congenital long-QT syndrome

    Circulation

    (2009)
  • Q. Wang et al.

    Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias

    Nat Genet

    (1996)
  • L. Crotti et al.

    NOS1AP is a genetic modifier of the long-QT syndrome

    Circulation

    (2009)
  • S. Zellerhoff et al.

    Atrial Arrhythmias in long-QT syndrome under daily life conditions: a nested case control study

    J Cardiovasc Electrophysiol

    (2009)
  • P.J. Schwartz et al.

    Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias

    Circulation

    (2001)
  • S.G. Priori et al.

    Risk stratification in the long-QT syndrome

    N Engl J Med

    (2003)
  • A.J. Moss et al.

    ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome

    Circulation

    (1995)
  • P.J. Schwartz et al.

    QTc behavior during exercise and genetic testing for the long-QT syndrome

    Circulation

    (2011)
  • P.J. Schwartz et al.

    Diagnostic criteria for the long QT syndrome. An update

    Circulation

    (1993)
  • R.W. Sy et al.

    Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands

    Circulation

    (2011)
  • Cited by (1402)

    • Precision therapy in congenital long QT syndrome

      2024, Trends in Cardiovascular Medicine
    View all citing articles on Scopus

    Developed in partnership with the Heart Rhythm Society (HRS), the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology, and the Asia Pacific Heart Rhythm Society (APHRS); and in collaboration with the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the Pediatric and Congenital Electrophysiology Society (PACES) and the Association for European Pediatric and Congenital Cardiology (AEPC).

    Representative for Association for European Pediatric and Congenital Cardiology

    Representative for Pediatric and Congenital Electrophysiology Society

    Representative for American Heart Association

    %

    Representative for American College of Cardiology

    View full text